Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook

Key Takeaways Ionis beat Q4 estimates, but shares fell 5% on a softer-than-expected 2026 revenue outlook.Commercial revenues jumped 64%, driven by Tryngolza sales and Dawnzera's first full quarterIonis guides 2026 revenues of $800M-$825M, below estimates, citing slower new drug uptakeIonis Pharmaceuticals (IONS) reported fourth-quarter 2025 adjusted loss per share of $1.14, narrower than the Zacks Consensus Estimate of a loss of $1.21. In the year-ago period, the company had incurred an adjusted loss of 43 ...